Arkolith/Insider Trading/AVTX/Form 4

Sullivan Christopher Ryan

Chief Financial OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed Apr 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$271K
Net Open-Market Flow
-$271K
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 2, 2026Sell(S)6K$17.02$106K19K
Apr 2, 2026Sell(S)2K$17.57$31K17K
Apr 1, 2026Sell(S)500$15.86$8K33K
Apr 1, 2026Sell(S)7K$16.83$126K25K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001810417-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML